Brief: Leads Biolabs Announces Partner Oblenio Bio’S $62 Million Oversubscribed Series B Financing To Advance Tri-Specific T-Cell Engager Lbl‑051 For Autoimmune Diseases Into Clinical Development
25/06/2026 12:21
BRIEF-Leads Biolabs Announces Partner Oblenio Bio’S $62 Million Oversubscribed Series B Financing To Advance Tri-Specific T-Cell Engager Lbl‑051 For Autoimmune Diseases Into Clinical Development June 25 (Reuters) - Nanjing Leads Biolabs Co Ltd 9887.HK:
LEADS BIOLABS ANNOUNCES PARTNER OBLENIO BIO’S $62 MILLION OVERSUBSCRIBED SERIES B FINANCING TO ADVANCE TRI-SPECIFIC T-CELL ENGAGER LBL‑051 FOR AUTOIMMUNE DISEASES INTO CLINICAL DEVELOPMENT
NANJING LEADS BIOLABS CO - SERIES B ROUND LED BY PFIZER VENTURES WITH DEEP TRACK CAPITAL, GV, AND ADITUM BIO
Source text: ID:nGNX9R9c4R
Further company coverage: 9887.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanjing Leads Biolabs
See all newsBrief: Nanjing Leads Biolabs Says FDA Grants Fast Track Designation To LBL-024
Brief: Nanjing Leads Biolabs Posts HY Loss Attributable RMB221.9 Million
Nanjing Leads rises on clinical study progress on cancer treatment drug
Nanjing Leads Biolabs jumps on progress of tumor antibody treatment
Nanjing Leads Biolabs rises on NMPA's IND approval for colorectal cancer